S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
NASDAQ:VTVT

vTv Therapeutics (VTVT) Stock Price, News & Analysis

$24.04
-0.70 (-2.83%)
(As of 04/19/2024 ET)
Today's Range
$23.81
$24.21
50-Day Range
$8.22
$29.00
52-Week Range
$7.38
$39.60
Volume
3,519 shs
Average Volume
10,469 shs
Market Capitalization
$72.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
VTVT stock logo

About vTv Therapeutics Stock (NASDAQ:VTVT)

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes that is in Phase III clinical trial; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases, psoriasis, COPD, and Atopic Dermatitis that is in Phase III clinical trial. It also develops TTP273, an orally available, small molecule glucagon-like peptide 1 receptor agonists for the treatment of cystic fibrosis related diabetes that is in Phase I clinical trial. In addition, the company is involved in the clinical development of other programs, including HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application in humans; and with Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator; with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

VTVT Stock Price History

VTVT Stock News Headlines

Incredible Opportunity to Retire FAST!
A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.
Incredible Opportunity to Retire FAST!
A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.
vTv Therapeutics Inc. (VTVT)
Nasdaq Down 50 Points; US Crude Stocks Rise By 4.2M Barrels
vTv Therapeutics Inc. Cl A
vTv Therapeutics Inc (VTVT)
vTv Therapeutics Inc - Ordinary Shares - Class A
See More Headlines
Receive VTVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/13/2024
Today
4/21/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VTVT
Employees
16
Year Founded
N/A

Profitability

Net Income
$-20,250,000.00
Pretax Margin
-306,833.34%

Debt

Sales & Book Value

Annual Sales
$2.02 million
Book Value
($9.27) per share

Miscellaneous

Free Float
2,959,000
Market Cap
$72.36 million
Optionable
Not Optionable
Beta
0.56
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Paul J. Sekhri M.Sc. (Age 66)
    CEO, President & Director
    Comp: $483.43k
  • Mr. Steven Tuch M.B.A. (Age 55)
    Executive VP & CFO
    Comp: $449.16k
  • Mr. Barry Brown (Age 63)
    Chief Accounting Officer
    Comp: $311.98k
  • Mr. Richard S. Nelson (Age 53)
    Executive VP of Corporate Development & Director
    Comp: $201.08k
  • Dr. Carmen Valcarce Ph.D.
    Chief Scientific Officer & Executive VP
  • Vanessa McDade
    Chief Administrative Officer
  • Ms. Elizabeth M. Keiley (Age 58)
    Executive VP & General Counsel
  • Dr. Thomas Strack M.D.
    Ph.D., Chief Medical Officer

VTVT Stock Analysis - Frequently Asked Questions

How have VTVT shares performed in 2024?

vTv Therapeutics' stock was trading at $11.50 at the start of the year. Since then, VTVT shares have increased by 109.0% and is now trading at $24.04.
View the best growth stocks for 2024 here
.

Are investors shorting vTv Therapeutics?

vTv Therapeutics saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 32,200 shares, a drop of 43.7% from the March 15th total of 57,200 shares. Based on an average daily volume of 73,400 shares, the short-interest ratio is currently 0.4 days. Currently, 6.1% of the shares of the company are sold short.
View vTv Therapeutics' Short Interest
.

When is vTv Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VTVT earnings forecast
.

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc. (NASDAQ:VTVT) posted its earnings results on Wednesday, March, 13th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter.

When did vTv Therapeutics' stock split?

Shares of vTv Therapeutics reverse split on the morning of Tuesday, November 21st 2023. The 1-40 reverse split was announced on Tuesday, November 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of vTv Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA).

When did vTv Therapeutics IPO?

vTv Therapeutics (VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

How do I buy shares of vTv Therapeutics?

Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VTVT) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners